Company
CellRep
AI-driven cell rejuvenation with small molecules
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
CellRep uses AI to discover small molecules that rejuvenate immune cells — without genetic modification. Our lead application enhances CAR-T therapy against solid tumors, where current treatments fail 90% of the time. Applied ex vivo during manufacturing, our compounds act as reagents that require no separate drug approval. With a first-in-human trial planned for 2026, we’re building the platform for cellular rejuvenation — from cancer immunotherapy to longevity.
Loading relationship preview